Amgen to present data from several Prolia studies at ASBMR 2011 meeting

[News]

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

More... (http://www.news-medical.net/news/20110819/Amgen-to-present-data-from-several-Prolia-studies-at-ASBMR-2011-meeting.aspx)